As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

and also has early-stage results for a next-generation candidate called amycretin. Last week, meanwhile, Pfizer selected a once-daily formulation of its oral GLP-1 drug danuglipron as its ...

In a plenary session at the annual American Academy of Neurology meeting, Paul Edison, MD, PhD, of Imperial College London in ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

One study found that GLP-1 drugs were associated with a 33 per cent reduction in the risk of dementia, while another class of diabetes medications, SGLT2 inhibitors, demonstrated an even greater ...

SGLT2 inhibitors such as empagliflozin, and GLP-1 agonists such as semaglutide (in people with both HFpEF and obesity). These drugs help people lose weight and have also been shown to reduce ...

The SOUL (NCT03914326) clinical trial is the first to assess the cardiovascular benefits of an oral GLP-1 inhibitor, building on its effectiveness aligns with injectable formulations. In an ...